Pages that link to "Q21099132"

The following pages link to alectinib (Q21099132):

Displaying 47 items.

• non-small-cell lung carcinoma (Q3658562) (← links)
• ALK receptor tyrosine kinase (Q21111336) (← links)
• EMAP like 4 (Q21113257) (← links)
• (Q21763219) (redirect page) (← links)
• ALK inhibitors in non-small cell lung cancer: the latest evidence and developments (Q26769879) (← links)
• alectinib(1+) (Q27162925) (← links)
• Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib (Q27853072) (← links)
• I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib (Q27853139) (← links)
• ALK Fusion (Q27908390) (← links)
• ALK EML4::ALK L1196M (Q28045565) (← links)
• Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance (Q28081606) (← links)
• ALK F1174L (Q28370065) (← links)
• ALK ALK Fusion G1202R (Q28371081) (← links)
• ALK EML4::ALK T1151INST (Q28371084) (← links)
• ALK ALK Fusion I1171 (Q28371483) (← links)
• ALK EML4::ALK V1180L (Q28371484) (← links)
• ALK ALK Fusion G1269A (Q28371512) (← links)
• RET Fusion (Q32965629) (← links)
• Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer (Q34449807) (← links)
• Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib (Q35007620) (← links)
• Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study) (Q36384499) (← links)
• Successful treatment of crizotinib-induced dysgeusia by switching to alectinib in ALK-positive non-small cell lung cancer (Q38354312) (← links)
• Alectinib for the treatment of ALK-positive stage IV non-small cell lung cancer (Q38422080) (← links)
• Novel ALK inhibitors in clinical use and development. (Q38427240) (← links)
• Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells (Q38810720) (← links)
• Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer. (Q38929017) (← links)
• Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer (Q38944638) (← links)
• Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases (Q38957939) (← links)
• Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance (Q38989221) (← links)
• Anaplastic lymphoma kinase regulates binge-like drinking and dopamine receptor sensitivity in the ventral tegmental area (Q40122376) (← links)
• Interstitial lung disease induced by alectinib (CH5424802/RO5424802). (Q41660655) (← links)
• Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. (Q45972765) (← links)
• ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression. (Q46187329) (← links)
• Alecensa (Q47520995) (← links)
• Rapid response of brain metastases to alectinib in a patient with non-small-cell lung cancer resistant to crizotinib. (Q48392520) (← links)
• Role and targeting of anaplastic lymphoma kinase in cancer (Q49888052) (← links)
• Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib. (Q52889775) (← links)
• Safety and effectiveness of alectinib in a real-world surveillance study in patients with ALK-positive non-small-cell lung cancer in Japan (Q64064515) (← links)
• Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion (Q64078853) (← links)
• Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases (Q64122275) (← links)
• Alectinib Approved for ALK+ Lung Cancer (Q87030858) (← links)
• ABCB1 Overexpression (Q105669091) (← links)
• (Q113456000) (redirect page) (← links)
• User:DeltaBot/fixClaims/maintenance/P715format (← links | edit)
• Wikidata:Database reports/Constraint violations/P2275 (← links | edit)
• Wikidata:Database reports/Constraint violations/P2892 (← links | edit)
• Wikidata:Database reports/Constraint violations/P4235 (← links | edit)